| Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis |
The following tables present the level in the fair value hierarchy at which the Company’s assets and liabilities are measured on a recurring basis (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total | | Fair Value Measurements Using Inputs Considered as: | | March 31, 2026 | | | | Level 1 | | Level 2 | | Level 3 | | Assets: | | | | | | | | | | | | | | | | | | | | | | Derivative assets - 2029 Capped Calls | | | | $ | 38,277 | | | $ | — | | | $ | — | | | $ | 38,277 | | Investment in convertible notes receivable | | | | 3,000 | | | — | | | — | | | 3,000 | | | | | | $ | 41,277 | | | $ | — | | | $ | — | | | $ | 41,277 | | | Liabilities: | | | | | | | | | | | | Derivative liabilities - freestanding instruments (FX) | | | | $ | 613 | | | $ | — | | | $ | 613 | | | $ | — | | Derivative liabilities - 2029 Embedded Derivative | | | | 93,254 | | | — | | | — | | | 93,254 | | ImThera contingent consideration arrangements | | | | 102,730 | | | — | | | — | | | 102,730 | | | | | | | | | | | | | | | | | $ | 196,597 | | | $ | — | | | $ | 613 | | | $ | 195,984 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total | | Fair Value Measurements Using Inputs Considered as: | | December 31, 2025 | | | | Level 1 | | Level 2 | | Level 3 | | Assets | | | | | | | | | | | | Derivative assets - freestanding instruments (FX) | | | | $ | 165 | | | $ | — | | | $ | 165 | | | $ | — | | Derivative assets - 2029 Capped Calls | | | | 36,551 | | | — | | | — | | | 36,551 | | Investment in convertible notes receivable | | | | 3,000 | | | — | | | — | | | 3,000 | | | | | | $ | 39,716 | | | $ | — | | | $ | 165 | | | $ | 39,551 | | | | | | | | | | | | | | Liabilities | | | | | | | | | | | Derivative liabilities - freestanding instruments (FX) | | | | $ | 99 | | | $ | — | | | $ | 99 | | | $ | — | | Derivative liabilities - 2029 Embedded Derivative | | | | 83,904 | | | — | | | — | | | 83,904 | | ImThera contingent consideration arrangements | | | | 92,075 | | | — | | | — | | | 92,075 | | | | | | | | | | | | | | | | | $ | 176,078 | | | $ | — | | | $ | 99 | | | $ | 175,979 | |
|
| Schedule of Recurring Fair Value Measurements Using Significant Unobservable Inputs |
The tables below present reconciliations of recurring fair value measurements that use significant unobservable inputs (Level 3) (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Derivative Assets - 2029 Capped Calls (1) | | Investment in Convertible Notes Receivable | | Derivative Liabilities - 2029 Embedded Derivative (1) | | ImThera Contingent Consideration Arrangements Liability | | December 31, 2025 | | $ | 36,551 | | | $ | 3,000 | | | $ | 83,904 | | | $ | 92,075 | | Changes in fair value (2) | | 1,726 | | | — | | | 9,350 | | | 10,655 | | | March 31, 2026 | | $ | 38,277 | | | $ | 3,000 | | | $ | 93,254 | | | $ | 102,730 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Derivative Assets - 2025 Capped Calls (1) | | Derivative Assets - 2029 Capped Calls (1) | | Derivative Liabilities - 2025 Embedded Derivative (1) | | Derivative Liabilities - 2029 Embedded Derivative (1) | | ImThera Contingent Consideration Arrangements Liability | | December 31, 2024 | | $ | 2,624 | | | $ | 23,735 | | | $ | 2,915 | | | $ | 51,819 | | | $ | 84,218 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Changes in fair value (2) | | (1,819) | | | (6,545) | | | (2,041) | | | (14,593) | | | 922 | | | March 31, 2025 | | $ | 805 | | | $ | 17,190 | | | $ | 874 | | | $ | 37,226 | | | $ | 85,140 | |
(1)Gains and losses are recorded in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss). (2)For the three months ended March 31, 2026, the contingent consideration change in fair value resulted in an increase of $1.1 million recorded to cost of sales and an increase of $9.6 million recorded to R&D. For the three months ended March 31, 2025, the contingent consideration change in fair value was primarily recorded to R&D.
|